Skip to main content
Clinical Trials/NCT04304131
NCT04304131CompletedNot Applicable

Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test

Kyung Hee University Hospital at Gangdong11 sites in 1 country1,210 target enrollmentStarted: June 7, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
1,210
Locations
11
Primary Endpoint
SDC2 methylation in stool DNA

Study Overview

Brief Summary

A study of colorectal cancer screening using stool DNA-based SDC2 methylation test

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Ages
12 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient who agreed the clinical trial and signed informed consent
  • High risk patient for colorectal cancer (family history of colorectal cancer, history of adenomatous polyp excision, inflammatory bowel disease > 15 years, or history of hereditary colorectal cancer)
  • Patient who scheduled to receive colonoscopy
  • Stool > 20g before bowel preparation for colonoscopy

Exclusion Criteria

  • No high risk patient under 60 years
  • History of colorectal cancer
  • Stool < 20g or sample after bowel preparation
  • Diarrhea or liquid stool which cannot be evaluated
  • Patient who is judged as not suitable for clinical trial including a psychiatric disorder by a physician

Outcomes

Primary Outcomes

SDC2 methylation in stool DNA

Time Frame: 1 year

positive ratio of SDC2 methylation

sensitivity and specificity of EarlyTect

Time Frame: 1 year

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Suk-Hwan Lee

Professor

Kyung Hee University Hospital at Gangdong

Study Sites (11)

Loading locations...

Similar Trials

Colorectal Cancer Screening Using Stool... | Clinical Trial